Science and Technology Innovation Center Guo Qiaoyu January 19, 2024
Diabetics can take probiotics.
Diabetes is one of the most common chronic diseases. Approximately one in 10 adults worldwide has diabetes, and the number of diabetes patients continues to increase worldwide. According to the International Diabetes Federation, the number of adults with diabetes worldwide will reach 537 million in 2021 and is expected to be 643 million by 2030, 783 million by 2045, and more than 1.31 billion people worldwide by 2050. Have diabetes. While the prevalence of diabetes continues to rise, its harm cannot be underestimated. According to statistics, diabetes can cause serious harm to the cardiovascular and cerebrovascular systems, kidneys, eyes, nervous system, and peripheral blood vessels. Its complications can even lead to kidney failure, disability, and even death.
At present, diabetic patients mainly achieve the purpose of controlling blood sugar by changing their lifestyle, injecting insulin, and using hypoglycemic drugs. However, these approaches do not always achieve adequate metabolic control, and many patients do not respond satisfactorily. Probiotic therapy is receiving increasing attention as a potential complementary strategy to pharmacological treatments.
Probiotics not only do not affect the condition of diabetics, but regular supplementation of probiotics can also regulate the body's blood sugar levels. Research shows that probiotics mainly regulate blood sugar through the following pathways: (1) regulating blood sugar by increasing adiponectin levels; (2) regulating blood sugar by inducing glucagon-like peptide-1 (GLP-1) secretion; (3) ) regulating blood sugar by improving insulin resistance; (4) regulates blood sugar by reducing inflammation levels; (5) regulates blood sugar by enhancing immunity; (6) regulates blood sugar by improving intestinal flora. Among them, inducing GLP-1 secretion is an important way for probiotics to regulate blood sugar. In recent years, targeted mining and screening of probiotics that can promote GLP-1 secretion have gradually become a research focus.
GLP-1 is an incretin hypoglycemic hormone that can inhibit obesity and alleviate diabetes through the following pathways: repairing the function of pancreatic beta cells, stimulating pancreatic beta cell division, and promoting insulin secretion; prolonging the transmission of hunger signals from intestinal cells to nerve centers The delivery time delays gastric emptying and reduces appetite; inhibits hepatic gluconeogenesis, promotes glucose uptake by the heart, reduces glucagon secretion, decreases renal glucose reabsorption levels, and lowers blood glucose concentration.
Two strains of HeheBio's Lactobacillus plantarum HH-LP 56 and Lactobacillus paracasei HH-LP 58 can well promote the body's secretion of GLP-1. We administered the compound probiotic powder of HH-LP 56 and HH-LP 58 into diabetic model rats and found that the probiotic powder could reduce the fasting blood sugar of the rats and increase the protein level of GLP-1 in the colon, indicating that Compound probiotic powder has a strong ability to induce GLP-1 secretion and can reduce blood sugar levels in diabetic patients.